AbbVie Becomes An Overnight Oncology Force With Pharmacyclics
This article was originally published in The Pink Sheet Daily
Executive Summary
The company outbid two rivals to win Pharmacyclics and its fast-growing cancer drug Imbruvica in an expensive acquisition that will cost AbbVie about $21 billion. But the fact that Pharmacyclics shares sales and profits on Imbruvica with J&J may leave some investors questioning the high premium.
You may also be interested in...
Stockwatch: Repeating Past Mistakes At AbbVie
AbbVie’s latest, largest acquisition may be cast in a new light as the pandemic throws stock markets into turmoil and commercial prospects up in the air.
Roche Pharma CEO Graham On Growth Prospects, Policy Pressures, Alzheimer’s And More
“I don’t think anybody can afford to not be in the Alzheimer’s race,” Graham said in one of her first public appearances since becoming CEO of Roche pharmaceuticals.
Commercial Fate Of Sarepta’s DMD Gene Therapy Remains Tied To EMBARK
The company guided investors to expect a narrow initial label under a US FDA accelerated approval for SRP-9001, with expansion possible based on EMBARK.